Requirement for expert histopathological assessment of ovarian cancer and borderline tumors.

2.50
Hdl Handle:
http://hdl.handle.net/10541/86649
Title:
Requirement for expert histopathological assessment of ovarian cancer and borderline tumors.
Authors:
Sengupta, P S; Shanks, Jonathan H; Buckley, C H; Ryder, W David J; Davies, Julie; Reynolds, K; Slade, Richard J; Kitchener, Henry C; Jayson, Gordon C ( 0000-0002-8515-8944 )
Abstract:
The distinction between borderline ovarian tumours (BOT) and ovarian carcinoma is made by histopathological assessment. Of 64 patients managed according to institutional BOT protocols, 27 (42%) had been referred with a diagnosis of ovarian carcinoma that was subsequently changed to BOT following histopathological review. The 70% 6-year event-free survival of the patients with a revised diagnosis was not significantly different from those who were referred with a diagnosis of BOT. This change in diagnosis is important as it avoids the need for chemotherapy for most patients and results in patients receiving appropriate information concerning prognosis. Interestingly, 24 patients (38.1%) reported a family history of epithelial cancer, a finding that has not been reported previously. Campaign
Affiliation:
Department of Medical Oncology, Christie Hospital National Health Trust, Withington, Manchester, UK.
Citation:
Requirement for expert histopathological assessment of ovarian cancer and borderline tumors. 2000, 82 (4):760-2 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Feb-2000
URI:
http://hdl.handle.net/10541/86649
DOI:
10.1054/bjoc.1999.0994
PubMed ID:
10732741
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorSengupta, P Sen
dc.contributor.authorShanks, Jonathan Hen
dc.contributor.authorBuckley, C Hen
dc.contributor.authorRyder, W David Jen
dc.contributor.authorDavies, Julieen
dc.contributor.authorReynolds, Ken
dc.contributor.authorSlade, Richard Jen
dc.contributor.authorKitchener, Henry Cen
dc.contributor.authorJayson, Gordon Cen
dc.date.accessioned2009-11-23T10:18:43Z-
dc.date.available2009-11-23T10:18:43Z-
dc.date.issued2000-02-
dc.identifier.citationRequirement for expert histopathological assessment of ovarian cancer and borderline tumors. 2000, 82 (4):760-2 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid10732741-
dc.identifier.doi10.1054/bjoc.1999.0994-
dc.identifier.urihttp://hdl.handle.net/10541/86649-
dc.description.abstractThe distinction between borderline ovarian tumours (BOT) and ovarian carcinoma is made by histopathological assessment. Of 64 patients managed according to institutional BOT protocols, 27 (42%) had been referred with a diagnosis of ovarian carcinoma that was subsequently changed to BOT following histopathological review. The 70% 6-year event-free survival of the patients with a revised diagnosis was not significantly different from those who were referred with a diagnosis of BOT. This change in diagnosis is important as it avoids the need for chemotherapy for most patients and results in patients receiving appropriate information concerning prognosis. Interestingly, 24 patients (38.1%) reported a family history of epithelial cancer, a finding that has not been reported previously. Campaignen
dc.language.isoenen
dc.subjectCancer Stagingen
dc.subjectOvarian Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshCell Differentiation-
dc.subject.meshDisease Progression-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Staging-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshRecurrence-
dc.titleRequirement for expert histopathological assessment of ovarian cancer and borderline tumors.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital National Health Trust, Withington, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.